Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources

PURPOSEPrior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more eff...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Diana del Cisne Pineda, Gabriel Berlingieri Polho, Yumi Ricucci Shinkado, Gustavo Alves Contado, Nathalia de Souza Crusoe, Vivian Naomi Horita, Joao Carlos Resende, Jamile Almeida Silva, Guilherme Fialho de Freitas, David Queiroz Muniz, Caio V. Suartz, Leopoldo Alves Ribeiro-Filho, Paulo M. Hoff, José Mauricio Mota
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society of Clinical Oncology 2025-04-01
Serie:	JCO Global Oncology
Accesso online:	https://ascopubs.org/doi/10.1200/GO-24-00464
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!